01-07-2001 | Original
A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
Published in: Intensive Care Medicine | Issue 7/2001
Login to get access